<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117534">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01700569</url>
  </required_header>
  <id_info>
    <org_study_id>ICO 2012-02</org_study_id>
    <secondary_id>2012-000774-31</secondary_id>
    <nct_id>NCT01700569</nct_id>
  </id_info>
  <brief_title>Phase-1 Study of Folinic Acid to Modulate MGMT Gene in Glioblastoma</brief_title>
  <acronym>FOLAGLI</acronym>
  <official_title>Phase I Study of Escalated Pharmacologic Dose, of Oral Folinic Acid in Combination With Temozolomide, According to Stupp R. Regimen, in Patients With Operated Grade-IV Astocytoma and a Non-methylated Gene Status of MGMT.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Cancerologie de l'Ouest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Antoine Lacassagne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Cancerologie de l'Ouest</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      O6-méthylguanine méthyltransférase (MGMT) is the main repair gene after DNA lesion induced
      by Temozolomide in combination with radiation therapy of Glioblastoma (GBM) in Stupp.R et al
      published regimen. In preclinical models, it has been demonstrated that MGMT methylation
      (which is silencing the DNA repair process) is achievable by folic acid. About half of the
      patients with operated GBM have an un-methylated MGMT gene status and therefore a poorer
      prognosis. A phase-1 dose escalation study is proposed with pharmacologic doses of folinic
      acid in combination with temozolomide and radiotherapy of operated GBM.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glioblastoma treated by Stupp regimen (Temozolomide + radiation therapy) have a different
      outcome depending on the methylation status of MGMT gene: when the gene is unmethylated, the
      repair process is active and the prognostic poor. In pre-clinical models, it has been
      demonstrated that Folic acid could re-methylate the MGMT gene and therefore the repair
      process to radiation and temozolomide could be limited, allowing a better prognosis. The
      proposed phase-1 study will explore the safety and efficacy of escalated doses of oral
      Folinic acid concomitantly with Stupp regimen. To determine the MTD is the main objective of
      the study, then the toxicty profile, the RDP2 and the methylation process efficacy at the
      MGMT gene level.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Maximal Tolerated Dose</measure>
    <time_frame>day 43</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>maximal tolerated dose 3x3 patients inclusion(modified Fibonnacci dose escalation )</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MGMT gene re-methylation</measure>
    <time_frame>day 43</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Year 1</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Grade IV Astrocytoma</condition>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Folinic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Folinic acid is given orally every day during the radiation therapy (47 days), then 5 days at each of the 6 maintenance cycle of temozolomide. The dose is escalated in a &quot;3x3&quot; method and the levels are: 5mg, 10mg, 15mg, 30mg, 60mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>All the Patients are treated by oral Temozolomide 75 mg/m²/day every day during 42 days, 30 minutes after Folinic acid and 120 min before the radiation dose to the brain tumor. After one month rest, the maintenance phase consists of:Temozolomide is given orally (30 min after Folinic acid), at 200 mg/m²/day every day during 5 days: one course every month during 6 months (6 maintenance course).</description>
    <arm_group_label>Folinic Acid</arm_group_label>
    <other_name>Temodal</other_name>
    <other_name>capsule dosage available: 5, 20, 10, 180 and 250 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>folinic acid at pharmacological dose is the escalated drug</intervention_name>
    <arm_group_label>Folinic Acid</arm_group_label>
    <other_name>Folinate de Calcium, Lederfoline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>High voltage radiation therapy (linear accelerator)</intervention_name>
    <description>Brain tumor field is irradiated Five days a week, during Stupp regimen during 6 weeks. During the sams time, Folinic acid and Temozolomide are given orally every days (six weeks).</description>
    <arm_group_label>Folinic Acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Operated GBM (complete or near complete resection)

          -  Un-methylated MGMT gene

        Exclusion Criteria:

          -  Non operable GBM

          -  Methylated MGMT
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario CAMPONE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Cancerologie de l'Ouest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francois PEIN, MD</last_name>
    <phone>+33240679908</phone>
    <email>francois.pein@ico.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>ICO site Gauducheau</name>
      <address>
        <city>Nantes</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Campone, MD, PhD</last_name>
      <phone>+33240679900</phone>
      <email>mario.campone@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Mario CAMPONE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean S FRESNEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987-96.</citation>
    <PMID>15758009</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 5, 2014</lastchanged_date>
  <firstreceived_date>September 12, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>high-grade</keyword>
  <keyword>glioma</keyword>
  <keyword>epigenetic</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
